Background The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is
generally poor. Recently, new classes of drugs (eg immune checkpoint inhibitors and small …

We undertook a systematic review of 41 randomised studies in disseminated melanoma,
identified by a comprehensive search. We aimed to investigate rates of response to various …

Summation Cancer immunotherapy consists of approaches that modify the host immune
system, and/or the utilization of components of the immune system, as cancer treatment …

Melanoma is a neoplasm with a rising incidence. Early‐stage melanoma is curable, but
advanced, metastatic melanoma almost uniformly is fatal, and patients with such advanced …

Metastatic melanoma is notoriously one of the most difficult cancers to treat. Although many
therapeutic regimens have been tested, very few achieve response rates greater than 25 …

The incidence of cutaneous melanoma has been rapidly increasing, with an estimate of
47,700 new cases diagnosed in 2000 in the United States. In the early phase of its natural …

The number of melanoma cases worldwide is increasing faster than any other cancer and
remains one of the most treatment-refractory malignancies. Despite decades of clinical trials …

Background: The addition of cytokines to chemotherapy (CT) has obtained encouraging but
contradictory results in metastatic melanoma. In this phase III trial, we compared the effects …

The incidence of melanoma is increasing, and the therapeutic options for unresectable
disease are limited, resulting in an increase in the death rate. Melanoma is usually resistant …

Purpose: To further investigate the efficacy and safety of temozolomide plus thalidomide in
patients with metastatic melanoma without brain metastases. Patients and Methods: Patients …